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ABSTRACT
Because natural killer (NK) cells can be potent anti-tumor effectors after allogeneic stem cell transplantation, we
investigated NK reconstitution and receptor expression in patients undergoing allogeneic hematopoietic stem
cell transplantation, focusing on the activating receptors that trigger anti-tumor responses. We determined
that NK levels in the peri-transplant period were inversely proportional to the dramatic rise and fall in plasma
levels of the NK homeostatic cytokine IL-15, which increased more than 50-fold from pretreatment to the
day of transplant during the lymphoreductive preparative regimen. Furthermore, in NK cells cultured with
IL-15, we observed an up-regulation of the activating receptors NKG2D, NKp30, and NKp46, associated
with an increase in anti-tumor lytic activity. Similarly, the expression of these activating receptors increased sig-
nificantly during the early post-transplant period, concurrent with a rapid increase in total NK cells and a shift
toward increased expression of CD56. These data suggest that the cytokine milieu of transplants, in particular
elevated levels of IL-15, may contribute to anti-tumor efficacy post-transplant by enhancing the recovery of NK
subsets and modulating expression of activating receptors.
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Natural killer (NK) cells play a critical role in the
innate immune response through their capacity to
lyse virally-infected or malignant cells without prior
antigen-specific priming. The triggering of this cyto-
toxicity, however, is tightly controlled through a bal-
ance of signals from the mix of functionally opposing
receptors found on each cell [1]. This balance acts as
a fail-safe wherein engagement of activating receptors
identifies potential targets, but engagement of inhibi-
tory receptors blocks killing of normal autologous
cells. Inhibitory receptors, such as the CD94–NKG2A
C-type lectin receptor heterodimers, recognize leader290peptides derived fromHLA–A, –B, or –C presented by
the non-classical class I molecule HLA–E. The fami-
lies of killer immunoglobulin-like receptors (KIR)
recognize polymorphic determinants of HLA–A, –B,
or –C. Normal autologous cells that express major his-
tocompatibility complex (MHC) class I are protected
from NK-mediated attack, but cells that have reduced
expression because of malignant transformation or
infection with viruses are then subject to attack [2, 3].
Two classes of activating receptors have been
linked to NK-mediated killing of tumor and virally in-
fected cells: NKG2D (CD314) and natural cytotoxic-
ity receptors (NCR). NKG2D binds to two distinct
NK-activating receptors increase post HSCT 291families of ligands, theMHC class I chain-related pep-
tides (MICA and MICB) and the UL-16 binding pro-
teins (ULBP). These ligands are up-regulated in cells
that have undergone neoplastic transformation; NK
cytotoxicity on tumor cells correlates with tumor ex-
pression of MICA and ULBP [4-6]. The NCRs,
Nkp30 (CD337) and NKp46 (CD335), bind to as yet
unidentified tumor antigens; are all activating recep-
tors; and are constitutively expressed on both resting
and activated NK cells. These receptors have been
demonstrated to be involved in NK cell-mediated
killing of multiple cancer cell lines [7]. Blockade of
NKG2D, especially in combination with NCR, re-
duces killing of a wide range of tumor cell lines [4, 5,
7]. Down-regulation of NKG2D and NCR receptors
by TGFb, moreover, has been associated with reduced
NK cytotoxicity [8-11]. These experiments demon-
strate: that NKG2D and NCR are critical to NK
anti-tumor cytotoxicity; that the expression of these
receptors can be modulated by the cytokine milieu;
and that such modulation can regulate the levels of
NK cytotoxicity.
Following either myeloablative or reduced inten-
sity (RIC) allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT), NK cells recover rapidly,
returning to normal levels within weeks [12-16]. Func-
tional assessments have shown that the rapid NK cell
reconstitution post-transplant is associatedwith a rapid
recovery of normal levels of NK cytotoxic activity [14,
17]. Peripheral blood NK cells can be divided into two
functional subsets based on surface expression ofCD56
[1]. NK cells that express high levels of the CD56 mol-
ecule (termed CD56bright) constitute about 10% of the
NK cells in the peripheral blood and play an immuno-
regulatory role through production of cytokines [1].
NK cells expressing lower levels of CD56 (CD56dim)
and high levels of CD16 (the Fcg receptor III) consti-
tute the remainder and are primarily cytotoxic effectors
[1]. An early increase in CD56bright NK cells has long
been reported [13], but recovery of NK subsets and
expression of receptors may reflect multiple factors
including: NK differentiation paths; cytokine milieu;
and graft-versus-host disease (GVHD) prophylaxis
[15, 18-20]. Receptor repertoire is in flux during NK
recovery; CD94/NKG2A inhibitory receptors recover
early to elevated levels, whereas killer immunoglobu-
lin-like receptors (KIR)may require long periods to re-
turn to normal levels [15, 21, 22]. Studies following
allo-HSCT have focused on the role of inhibitory re-
ceptors, particularly KIR receptors capable of distin-
guishing allogeneic MHC antigens [23-25], with little
information about the role of activating receptors in
anti-tumor activity [15]. The balance of signals from
the NK cell receptor repertoire determines overall
NK cell activity. Therefore, NK activity against tu-
mors, during the critical period of minimal residual
disease post-transplant, may be dependent not onlyupon the rate of reconstitution of NK cell numbers,
but also upon the recovery of the repertoire of activat-
ing as well as inhibitory receptors.
In this study, we analyzed the reconstitution of NK
cells and their receptor repertoire in adult patients un-
dergoing allo-HSCT under an RIC regimen involving
doses of cytoxan and fludarabine specifically designed
to deplete lymphocytes [26, 27]. We determined that
the levels of IL-15, a critical cytokine in NK differen-
tiation, activation and homeostasis, underwent dra-
matic changes in the peri-transplant period, in an
inverse relationship to the numbers of NK cells pres-
ent. Furthermore, we determined that, in normal NK
cells, IL-15 rapidly up-regulated the levels of critical
activating receptors: NKG2D, NKp30, and NKp46.
This IL-15 induced increase in expression was corre-
lated withmarked increases in cytotoxic activity, which
could be blocked by neutralizing antibodies against
these receptors. Finally, we determined that the expres-
sion of these key activating receptors (ie NKG2D,
NKp30 and NKp46) was increased in the early post-
transplant period and that these increases were main-
tained for at least 3months post-transplant. Therefore,
the IL-15 rich cytokine milieu post-transplant may
drive both the recovery of NK populations and the
elevated expression of their activating receptors.
MATERIALS AND METHODS
Patients and Donors
Fourteen patients (11 males, 3 females) underwent
reduced intensity allogeneic transplants from HLA-
identical related donors for treatment of hematologic
malignancies (Table 1). The study was approved by
the Institutional Review Board of the National Cancer
Institute and informed consent was obtained from all
participants.
Table 1. Patient Characteristics
Patient Age Sex Diagnosis Stage
Prior
Therapies
Induction
Cycles
1 61 m HD IV 2 3
2 50 m NHL II 6 1
3 53 m NHL IV 4 1
4 71 f CLL IV 2 3
5 31 m HD III 2 3
6 39 m HD IVB 3 3
7 39 m NHL IV 2 1
8 69 m NHL IV 6 2
9 32 m NHL III 4 2
10 59 f NHL IIIB 5 1
11 52 m CLL II 4 3
12 33 f HD IV 5 3
13 60 m MDS 4 1
14 58 m My 1 3
HD indicates Hodgkin Disease; NHL, Non-Hodgkin Lymphoma;
CLL, Chronic lymphocytic leukemia; MDS, Myelodysplastic
syndromes; My, Myelofibrosis.
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The goal of the induction regimen was to achieve
severe, targeted host immune T cell depletion prior to
allogeneic HSCT in order to attain rapid conversion
to full donor chimerism and to facilitate the develop-
ment of a graft versus tumor effect soon after trans-
plantation [26, 27]. To reduce CD4 counts to fewer
than 100 cells/ml prior to the transplant preparative
regimen, all patients received from 1 to a maximum
of 3 cycles of an induction regimen of fludarabine
(25mg/m2 i.v. daily, days 1-4) in combination with
the agents contained in the EPOCH regimen (etopo-
side 50 mg/m2 i.v. days 1-4, doxorubicin 10 mg/m2
i.v. days 1-4, vincristine 0.4 mg/m2 i.v. days 1-4,
cyclophosphamide 750 mg/m2 i.v., day 5 and predni-
sone 60 mg/m2 PO daily, days 1-5). Patients with
CD201 lymphoid malignancies also received rituxi-
mab 375 mg/m2 i.v. on day 1 of each treatment cycle.
The transplant preparative chemotherapy regimen
consisted of fludarabine (30 mg/m2 per day i.v. infu-
sion daily for 4 days) and cyclophosphamide (1200
mg/m2 per day i.v. infusion daily for 4 days). On
transplant day 0, patients received non-manipulated
peripheral blood progenitor cells from their HLA-
matched sibling donors [27].
Prophylaxis Against GVHD
Patients received cyclosporine (dose adjusted to
200 ng/ml) beginning at day -1, and gradually tapering
from day 100 to day 180 post-transplant. Patients also
received intravenous methotrexate 5 mg/m2 on days
11, 13, 16, and 111 post-transplant.
Sample Collection and Evaluation
Peripheral blood was collected prior to the initia-
tion of the induction regimen, the day of the trans-
plant, and on days 14, 28, 60, 90, 180, 270, and 365
days after transplantation. Flow cytometry was per-
formed using whole blood lysis in a Clinical Labo-
ratory Improvement Amendments (CLIA) certified
laboratory (Science Applications International Corpo-
ration, Frederick, MD, USA). The absolute number of
NK cells (CD3-and CD561) per liter of blood was cal-
culated based upon the percentages of these cells in the
lymphocyte gate, the percentage of lymphocytes (de-
fined as CD45bright, CD14-, low side scatter) and the
white cell blood counts.
Assessment of Chimerism
Chimerism analysis was performed by assessing
the variable number of tandem repeats by polymerase
chain reaction method in a CLIA-certified laboratory
at the Blood Center of Southeastern Wisconsin
(Milwaukee, WI, USA).Interleukin-15 Levels
The IL-15 QuantiGlo ELISA (R&D Systems) was
used to measure the patient’s levels of plasma IL-15
prior to therapy with the induction regimen, the day
of the transplant, and on days 14, 28, 60, 90, 180,
270, and 365 days after transplantation.
Cell Culture and IL-15 Stimulation
NK cells were isolated from peripheral blood
mononuclear cells of healthy donors using magnetic
beads (Miltenyi Biotec). NK cells were cultured in
complete medium (CM – RPMI-1640 [InVitrogen-
Lifetech] supplemented with 10% FCS, L-glutamine,
sodium pyruvate, non-essential amino acids and peni-
cillin/streptomycin) and were stimulated with rhIL-15
(Peprotech) at concentrations from10-100ng/ml.Cells
were harvested after 1, 3, 7, and 14 days and the NK
receptor repertoire were assessed by multi-parameter
flow cytometry.
Immunophenotyping Analysis
The reconstitution of the two NK subsets
(CD56dim CD161 and CD56brightCD16–) and their
receptor expression were evaluated at 28, 90, 180, and
365 days post-transplant and was compared to that
found in the peripheral blood stem cells (PBSC) apher-
esis as a standard control. Monoclonal PE conjugated
antibodies toNKp30,NKp46, (Beckman-Coulter-Im-
munotech), and NKG2D (R&D systems) were used in
combination with anti-CD3 APC and anti-CD16
FITC and biotinylated anti-human CD56 (BD Biosci-
ences-Pharmingen) followed by streptavidin PE-Cy5
(Invitrogen-Caltag). Flow cytometric analysis was per-
formed on a FACSort flow cytometer (Becton Dickin-
son) using CellQuest software. Further analysis was
performed using Flow-Jo software (Treestar).
NK Cytotoxicity Assay
NK activity was assessed in 4-h 51Cr release assays
using K562 targets as previously described [28, 29].
Briefly, target cells were labeled with 100 mCi of
51Cr for 1 h at 37C at 5% CO2. The labeled cells
were washed twice in CM, re-suspended in CM, and
the viable cell counts were performed. Cells were
co-incubated for 4 h at 37C at effector to target
(E:T) ratios of 6, 3, 1.5, and 0.75 to 1. Co-cultures
were set up in triplicate. Controls included: targets in-
cubated in medium alone for spontaneous release; and
targets in 5% (v/v) Triton X-100 in PBS for maximum
release. Radioactivity was measured byWallacWizard
1470 Automatic Gamma Counter. The percentage of
cytotoxic activity was calculated using the following
formula: % specific lysis 5 (sample cpm–spontaneous
cpm)/(maximal cpm–spontaneous cpm)  100%.
Lytic Units (LU) were calculated as the number of
effector cells needed to lyse 20% of 5 X 103 target cells,
NK-activating receptors increase post HSCT 293and expressed as LU/107 cells. For the blocking assays,
blocking antibodies to NKG2D, NKp46, and NKp30
were added to the NK cultures 1 hour prior to con-
ducting the NK cytotoxicity assays.
Statistical Analysis
Because the cell population counts were generally
not normally distributed, we report medians and
ranges for parameter values. We used non-parametric
statistical methods in the analyses. All paired differ-
ences between cells measured from the same patients
at two different time points were tested using theWil-
coxon signed rank test. For comparison of NK cells
between two groups of patients, the exact Wilcoxon
rank sum test was used. Correlations were performed
using the Spearman rank correlation.
RESULTS
NK Cell Reconstitution Following HSCT is
Inversely Correlated to Plasma IL-15 Levels
On the day of the transplant in all patients, the NK
levels had been reduced by the lymphodepleting regi-
men of fludarabine-cytoxan to 0 cells/ml. Subsequent
NK cell recovery was rapid. By 4 weeks, the NK cell
levels reached a peak level higher than those in the orig-
inal host (226 cells/ml; range 63-701 cells/ml) and, by
the second month post-transplant, the median NK
levels had decreased to host pre-transplant levels (77
cells/ml, range 22-374). These levels were maintained
through the first post-transplant year (Figure 1A). By
1 month post-transplant, all patients had greater than
90% donor chimerism in the lymphoid compartment.
Because of the rapid recovery of NK cells follow-
ing this lympho-depleting transplant regimen, we in-
vestigated the levels of IL-15 in the peri-transplant
period. On the day of transplant, the IL-15 levels
were increased an average of 50-fold from the pre-
treatment levels, to a median of 57.2 pg/ml (range
30.3-147.2 pg/ml). Concurrent with the rapid recovery
of NK cell levels at 2 weeks, the IL-15 levels in the pe-
ripheral blood declined to median level of 17.2 pg/ml
(range, 5.5-54.2). By 4 weeks post-transplant, the IL-
15 levels had fallen to 2.95 pg/ml (range, 0.2-20.0)
and, by 6 months post-transplant, IL-15 levels re-
turned to and maintained pre-transplant levels.
(Figure 1A). NK levels assessed during the transplant
and year-long recovery process correlated inversely
with the levels of IL-15 measured in the plasma
(Figure 1B).
All lymphocyte populations are depleted during
transplant conditioning, however, so the specific cor-
relation of IL-15 and NK populations was tested dur-
ing a period of rapid early NK recovery, when other
populations remained low. NK numbers and IL-15
levels in individual patients were compared at 2 weeks
post-transplant, a time point of rapid change anda broad variation in individual NK recovery (Fig-
ure 1C). A strong inverse relationship was found
(Spearman correlation r520.805,P5 .0037). This in-
verse relationship between circulating cytokine levels
and cytokine-consuming NK levels is consistent with
a homeostatic relationship, that is, plasma IL-15 levels
are defined primarily by consumption, rising during
lympho-depletion and falling upon NK recovery.
IL-15 Increases the Expression of Activating NK
Cells Receptors
To assess the effect of IL-15 on the NK cell recep-
tor expression, we cultured NK cells sorted from
normal healthy donors with IL-15. We observed an
up-regulation of the NK cell activating receptors
NKG2D, NKp30, and NKp46, encompassing both
increases in the percentages of cells expressing the re-
ceptors and the MFI of each receptor. These changes
were evident as early as 24 h after the start of culture,
reached a maximum within 72 h, and were maintained
as long as 14 days in culture (Figure 2A). Expression of
CD56 increased on all NK cells in these cultures.
Based on expression of CD16 to distinguish NK sub-
sets, comparable levels of activating receptor expres-
sion were achieved in both the CD561CD161 and
the CD56brightCD16– NK subsets (Figure 2B).
When sorted CD56bright and CD56dimCD161 NK
were separately cultured with IL-15, the CD56bright
NK cells expanded more than CD56dimCD161 NK
cells in culture, but bothNK populations up-regulated
activating receptor expression.
Concomitant with the up-regulation of the activat-
ing receptors following 3 days of IL-15 stimulation,
there was a significant increase (P \ .0001) in NK
cell cytotoxicity on K562 targets (1647 vs 5477 LU)
(Figure 2C). Expression of multiple activating and in-
hibitory receptors is altered in response to culture in
IL-15, however, so the contribution of the changes
in activating receptors was assessed by the addition
of neutralizing antibodies to the cytotoxicity assays.
Addition of antibodies to any of the 3 receptors
reduced the level of cytotoxicity and addition of all 3
antibodies blocked much of the increase in NK cyto-
toxicity (5477 to 2434 LU, P \ .001) (Figure 2C).
Therefore the increase in cytotoxic activity following
IL-15 culture was to a large extent dependent upon
the increase in expression of NKG2D and NCR acti-
vating receptors.
Activating Receptor Expression Post-Transplant
We then examined the changes in the expression of
the 3 activating receptors in 14 donor/recipient pairs,
examining the NK cells in donor PBSC aphereses and
in patient peripheral blood collected in the year fol-
lowing transplant. We observed the greatest changes
in the early post-transplantmonths, the period in which
the highest levels of IL-15 were observed.
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Figure 1.Correlation of NK cell recovery with IL-15 during the post-transplant period. A) Time courses of NK levels (cells/ml) (white squares)
and plasma IL-15 levels (pg/ml) (black circles). NK cells recover rapidly post transplant, reaching a peak at 1month and declining to pretreatment
levels for the first year post-transplant. The plasma levels of IL-15 in the peri-transplant period reached a peak at the day of transplant and de-
clined sharply in the first month. B) Inverse relationship overall between NK cell numbers and plasma IL-15 levels at all time points in the first
year. C) Strong inverse correlation between NK cell numbers and plasma IL-15 levels at 2 weeks post-transplant, a time when NK populations
were rapidly recovering and IL-15 levels varied over a 10-fold range. Spearman non-parametric correlation r values are shown.Expression of the activating receptors was signifi-
cantly increased in the early months post-transplant
as compared with the expression in the donor PBSC.
As in the cultured NK cells, there was a significant in-
crease in the level of expression of CD56. The greatest
expression of the activating receptors was observed on
those cells with the highest levels mean fluorescence
intensity (MFI) of expression of CD56 (Figure 3).
Expression of the homodimeric activating receptor
NKG2D increased significantly from amedian of 41%
(range 14 – 80%) of NK cells in PBSC to 60% (range
24 – 89) of the NK cells at 1 month. Meanwhile the
MFI of NKG2D increased from 12 (range 6-35) in
the donor inoculum to 21 (range 10-41) at 1 month
(Figure 3, Figure 4) Although NK cells in some indi-
viduals continued to express high levels of NKG2D
(Figure 3), in general this marker declined by 3
months. Similarly the frequency of NK cells express-
ing NKp30 (CD337) at 1 month post-transplant was
twice that of NK cells in the PBSC, but expression of
this marker remained significantly elevated at 3
months. Expression of NKp46 (CD335) showed thegreatest change. Expression tripled from 20% (range
8-57) of the total NK cells in the donor apheresis to
a median of 63% (range 35-84) at 1 month and re-
mained elevated in both frequency and MFI at 3
months (P 5 .003) (Figure 3, Figure 4). By 6 months
the median expression of these markers had returned
to levels in the donor apheresis, but remained elevated
as long as 1 year in some individuals.
No significant increases were observed in KIR or
NKG2C expression in these patients (data not shown).
Expression of NKG2A and CD94 increased (data not
shown), consistent with previous reports [21, 30].
Receptor Association with NK Subset Recovery
We found that the MFI of the 3 activating NK
receptors was usually observed on those cells with
the highest CD56 expression (Figure 3). As has previ-
ously been observed in transplant regimens [13], there
was a disproportionate increase of the CD56bright
CD16– subset of NK cells at 1 month compared to
the increase of the CD56dimCD161 subset. By 3
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Figure 3. Expression of NK receptors during the first year post-transplant. Contour plots of gated NK cells from patient #14 over a time course
of the first year post-transplant. At 1 month post-transplant, the proportion of CD56brightCD16– cells within the NK population increased. In
addition, an overall increase in the expression of CD56 was observed on both NK subsets. Expression of the activating NKG2D, NKp30, and
NKp46 receptors increased onNK cells in the early months post-transplant relative to that of the donor PBSCNK cells. The highest level (MFI)
of activating receptor expression was found on cells that had up-regulated CD56 expression.months post-transplant, the proportion of NK cells in
the CD56brightCD16– subset was declining toward
normal ratios, which were then maintained for the first
year (Figure 5A). We therefore examined whether or
not there was a differential expression of activating
NK receptors in the 2 subsets, such that the increase
in CD56brightCD16– would be responsible for the in-
creased frequency of activating receptors. We deter-
mined that a higher frequency of NK cells in the
CD56brightCD16– subset expressed NKG2D at 1 and
3 months, but the increase in expression of the NCR
receptors were comparable in both subsets. Further-
more, the MFI of NKp46 was much higher in the
CD56brightCD16– subset (Figure 5B, C), but other
receptors were expressed at comparable intensities.
Overall, therefore, both the CD56brightCD16– subsetand the CD56dimCD161 subset had increased expres-
sion of activating receptors in the first months post-
transplant.
DISCUSSION
In this study,we examined the reconstitution ofNK
cells and their receptor repertoire in patients with
hematologic malignancies who had undergone allo-
HSCT under a lympho-depleting, non-myeloablative
regimen. We demonstrated that the expression of the
activating receptors on NK cells increased during the
early post-transplant period, at the time whenNK cells
not only constituted a significant percentage of the
lymphocyte population, but also achieved circulating
levels not achieved for the remainder of the first
NK-activating receptors increase post HSCT 297post-transplant year. We have documented signifi-
cantly elevated IL-15 levels in all patients in this study
on the day of transplant and a subsequent decline cor-
related with NK recovery, consistent with homeostatic
dynamics. Furthermore,we have demonstrated that the
increased expression of activating receptors and the
concomitant increase in NK cytotoxicity can be in-
duced in vitro by IL-15. We propose that the cytokine
milieu present during the early post-transplant period
may underlie the rapid changes in the NK populations
and activating receptor expression. Because of the crit-
ical role these activating receptors have in anti-tumor
reactivity, these changes may underlie NK efficacy on
residual disease post-transplant.
Plasma IL-15 levels have been demonstrated to in-
crease significantly following cytoreductive therapy
[31, 32]. As IL-15 is constitutively produced [33], the
elevated plasma IL-15 levels could be related to trans-
plant regimen-induced depletion of lymphoid popula-
tions that normally consume circulating IL-15,
paralleling the postulated homeostatic relationship of
serum IL-7 levels and T cell reconstitution [34]. Miller
et al [32] have demonstrated that a high dose fludara-
bine/cytoxan chemotherapy regimen can result in ele-
vated serum IL-15 levels that were not observed in
regimens producing less lympho-depletion.
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Figure 4. Percentile plots of NK receptor expression in the first year
post-transplant. Box plots of percentages ofNK cells expressing each
receptor, showing the median (central bar), 25th and 75th percentile
(box) and 10th and 90th percentile (bar) from the patients. Wilcoxon
paired signed rank P values comparing expression in donor PBSCT
and at 1 and 3 months post-transplant are indicated.In the current study, the non-myeloablative reg-
imen specifically focused upon the use of inductive
chemotherapy and preparative regimens designed to
deplete host lymphocyte populations and produce
rapid donor engraftment [26, 27]. Depletion of NK
cells was particularly effective; no hosts had residual
NK cells at day 0. IL-15 could also have been aug-
mented in response to inflammatory stimulation
induced by the transplant regimen [35, 36]. Both
may have contributed to the highly elevated levels
of IL-15 were found in all patients on the day of
transplant.
Elevated levels of IL-15 at the time of transplant
could support both NK differentiation and expansion.
The growth, differentiation, and survival of NK cells
have been found to be dependent upon IL-15. Mice
lacking expression of either IL-15 or the IL-15Ra
chain fail to develop NK cells; NK cells transferred
into IL-15–/– hosts fail to survive [37-39]. In humans,
IL-15 induces the differentiation of NK cells in
stroma-free cultures from CD341 progenitor cells
and expands mature NK cells in culture [1, 19, 20].
NK clones administered as adoptive therapy persisted
and expanded only in patients receiving a lympho-
depletive regimen resulting in high IL-15 levels [32].
In our study, the rapid decline in IL-15 levels we
observed was strongly correlated with the rapid
recovery of NK levels. This was particularly evident
at 2 weeks, when the broad range of IL-15 levels
present in the patients demonstrated a strong inverse
correlation with NK recovery in individual patients.
This is the first demonstration that the decline in IL-
15 following transplantation is specifically correlated
with NK recovery.
Both generation of new NK cells from donor stem
cells and expansion of NK cells transferred in the do-
nor inoculum may have contributed to the NK popu-
lations present at 1 month. The CD56bright NK subset
was disproportionately increased at 1 month relative to
the CD56dimCD16– subset, consistent with previous
reports [13, 18]. In vitro IL-15 has been demonstrated
to induce differentiation of hematopoietic progenitor
cells into NK cells that primarily express the
CD56bright phenotype [1, 19, 40]. The early increase
in CD56bright NK cells is consistent with evidence
that donor stem cells rapidly differentiate into NK
cells post-transplant [12, 15]. CD56bright cells present
in the donor PBSC inoculum may also have expanded
disproportionately in the presence of high endogenous
levels of IL-15. We and others have observed that
CD56bright NK cells proliferate more than the
CD56dim subset in IL-15 stimulated cultures [18].
Thus, whether derived from hematopoietic stem cells
or from CD56bright NK cells in the donor inoculum,
the shift in the NK subset proportions could have
been driven by the elevated levels of IL-15 observed
during the early post-transplant period.
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Figure 5.NK subset and receptor recovery. A) Stacked bar graph of the average number of CD56brightCD16– and CD56dim CD161NK cells/ml
of peripheral blood in donor peripheral blood and in recipients post-transplant. At 1 month post-transplant the CD56brightCD16– subset (black
bar) was disproportionately increased compared to the CD56dim CD161 (white bar). Standard error bars for each subset are shown. B) Overlay
histograms illustrating increased expression of activating receptors in both NK subsets in a representative patient (#2) at 1 and 3 months post-
transplant. Gray filled histogram shows donor PBSC NK cells; black line shows 1 month post-transplant; thick black line shows 3 months post-
transplant. C) Scatterplots of the expression of the activating receptors in NK subsets in donor PBSC and patient peripheral blood following
transplant. Horizontal bars represent the median expression of the receptors in the donor group, and at 1 and 3 months post-transplant.Culture of progenitor cells in IL-15 has also been
demonstrated to promote the step-wise differentiation
of inhibitory and activating NK receptors [18, 19, 40,
41]. We demonstrated that mature circulating NK
cells will also up-regulate the expression of these re-
ceptors under the influence of IL-15, with a concomi-
tant increase in receptor-dependent cytotoxic activity
on an NK tumor target cell line. The NCRs, NKp30
and NKp46, and the C-type lectin receptor NKG2D
were significantly elevated at 1 month post-transplant
and elevated levels of expression persisted in some pa-
tients up to 12 months post-transplant. Furthermore
both the CD56brightCD16– and the CD56dimCD161
populations demonstrated increases in both thefrequency of cells expressing the receptors and the
MFI level of expression/cell.
An additional transplant regimen-related factor
that might have contributed to the rapid expansion
of NK cells and the shift in receptor expression is the
use of cyclosporin as a primary prophylactic measure
for acute GVHD (aGVHD). Patients were maintained
on cyclosporin at a dose adjusted level of 200 ng/ml for
the first 100 days, with subsequent tapering till 180
days. Addition of Cyclosporin A to IL-15-stimulated
NK cultures has been found to synergize with many
of the effects of IL-15 alone, including increased
expression of CD56bright NK cells and increased
expression of NKp30, although not NKG2D [20].
NK-activating receptors increase post HSCT 299The contribution of cyclosporin as GVHD pro-
phylaxis to NK efficacy on residual disease remains
undetermined. Nevertheless, this work suggests that
multiple transplant-regimen related factors–severe
host lympho-depletion elevating endogenous IL-15
levels, non-manipulated PBSC infusion containing
mature NK cells, and post-transplant prophylaxis sup-
porting IL-15 effects–may work together to establish
a rapid engraftment of donor NK cells with elevated
expression of tumor-reactive activating receptors.
NK cells have long been found to be effective in
killing a broad range of tumor cells. The role of NK
cells in enhancing graft-versus-leukemia (GVL) in
allogeneic transplants has been demonstrated in both
in vivo preclinical and clinical studies [42, 43]. Recent
studies have shown that transplantation from T cell-
depleted donors, whose NK cells were reactive against
haploidentical host MHC, protected patients with
acute myelogenous leukemia (AML) from relapse
[24, 25, 44]. The post-transplant period provides an
opportunity for enhanced NK-mediated attack on
residual tumor cells. NK cell numbers are elevated,
particularly the CD56bright populations. Expression
of the critical anti-tumor receptors NKp30, NKp46,
and NKG2D are elevated. The evidence presented
here suggests that these population and receptor shifts
are not random, but are driven by the cytokine milieu
of transplant, specifically the elevated plasma levels of
IL-15. Thismodel linking homeostatic cytokine levels,
NK expansion, and expression of activating receptors
targeting tumor antigens, therefore supports the use
of transplant-based regimens as a platform for NK-
based therapies and provides insights into the biology
that may direct intervention strategies.
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